90 related articles for article (PubMed ID: 20638714)
1. Is HAART modifying the HIV epidemic?
Maggiolo F; Leone S
Lancet; 2010 Aug; 376(9740):492-3. PubMed ID: 20638714
[No Abstract] [Full Text] [Related]
2. Is antiretroviral therapy modifying the HIV epidemic?
Shelton JD; Cohen M; Barnhart M; Hallett T
Lancet; 2010 Nov; 376(9755):1824-5; author reply 1825. PubMed ID: 21111901
[No Abstract] [Full Text] [Related]
3. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
[TBL] [Abstract][Full Text] [Related]
4. Is antiretroviral therapy modifying the HIV epidemic?
Grulich AE; Wilson DP
Lancet; 2010 Nov; 376(9755):1824; author reply 1825. PubMed ID: 21111902
[No Abstract] [Full Text] [Related]
5. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
[TBL] [Abstract][Full Text] [Related]
6. Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.
Knapp DJ; Brumme ZL; Huang SY; Wynhoven B; Dong WW; Mo T; Harrigan PR; Brumme CJ
Clin Infect Dis; 2012 Jun; 54(11):1652-9. PubMed ID: 22460975
[TBL] [Abstract][Full Text] [Related]
7. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
8. Outpatient pharmacy care and HIV viral load response among patients on HAART.
Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner JS; Hogg RS
AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of antiretroviral multiclass resistance.
Lima VD; Harrigan PR; Sénécal M; Yip B; Druyts E; Hogg RS; Montaner JS
Am J Epidemiol; 2010 Aug; 172(4):460-8. PubMed ID: 20667931
[TBL] [Abstract][Full Text] [Related]
10. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
11. HIV infection in IVDUs decreases with expanded HIV treatment coverage.
AIDS Patient Care STDS; 2010 Apr; 24(4):266. PubMed ID: 20405530
[No Abstract] [Full Text] [Related]
12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
13. Parallel evolutions of the growth rate of newly diagnosed HIV cases and the proportion of potentially infective patients in Cayenne French Guiana: should HAART be used to curb the epidemic?
Nacher M; Vantilcke V; Huber F; El Guedj M; Vaz T; Magnien C; Djossou F; Mahamat A; Dabis F; Couppié P
Public Health; 2009 Aug; 123(8):573-4. PubMed ID: 19692100
[No Abstract] [Full Text] [Related]
14. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART.
Belmonte L; Olmos M; Fanin A; Parodi C; Baré P; Concetti H; Pérez H; de Bracco MM; Cahn P
AIDS; 2007 Oct; 21(15):2106-8. PubMed ID: 17885303
[TBL] [Abstract][Full Text] [Related]
15. [Antiretroviral therapy in 2004].
Jablonowski H
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
[TBL] [Abstract][Full Text] [Related]
16. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
Gibellini D; Borderi M; De Crignis E; Cicola R; Cimatti L; Vitone F; Chiodo F; Re MC
J Infect; 2008 Mar; 56(3):219-25. PubMed ID: 18276011
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures.
La Sala GB; Pilotti E; Nicoli A; Pinelli S; Villani MT; Ronzi P; Zendri E; Re MC; Magnani G; Casoli C
AIDS; 2007 Jan; 21(3):377-9. PubMed ID: 17255749
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
20. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
